159 related articles for article (PubMed ID: 21427555)
61. [Molecular biology of colorectal cancer in clinical practice].
Kit OI; Vodolazhsky DI
Mol Biol (Mosk); 2015; 49(4):531-40. PubMed ID: 26299852
[TBL] [Abstract][Full Text] [Related]
62. Colorectal Cancer Subtypes - The Current Portrait.
Jordan P
Adv Exp Med Biol; 2018; 1110():1-6. PubMed ID: 30623362
[TBL] [Abstract][Full Text] [Related]
63. The current state of targeted agents in rectal cancer.
Kim DD; Eng C
Int J Surg Oncol; 2012; 2012():406830. PubMed ID: 22675625
[TBL] [Abstract][Full Text] [Related]
64. Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status.
Lee JK; Chan AT
Curr Colorectal Cancer Rep; 2011 Jun; 7(2):136-144. PubMed ID: 21572547
[TBL] [Abstract][Full Text] [Related]
65. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
66. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.
Roepman P; Schlicker A; Tabernero J; Majewski I; Tian S; Moreno V; Snel MH; Chresta CM; Rosenberg R; Nitsche U; Macarulla T; Capella G; Salazar R; Orphanides G; Wessels LF; Bernards R; Simon IM
Int J Cancer; 2014 Feb; 134(3):552-62. PubMed ID: 23852808
[TBL] [Abstract][Full Text] [Related]
67. Personalized medicine in lung cancer: what we need to know.
Mok TS
Nat Rev Clin Oncol; 2011 Aug; 8(11):661-8. PubMed ID: 21862980
[TBL] [Abstract][Full Text] [Related]
68. Recent advances in personalized colorectal cancer research.
Kraus S; Nabiochtchikov I; Shapira S; Arber N
Cancer Lett; 2014 May; 347(1):15-21. PubMed ID: 24491406
[TBL] [Abstract][Full Text] [Related]
69. Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review.
Dai P; Ye Z; Cai Z; Luo Z; Qiu E; Lin Y; Cai J; Wang H; Li Z; Han S
BMC Gastroenterol; 2022 Feb; 22(1):65. PubMed ID: 35164703
[TBL] [Abstract][Full Text] [Related]
70. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
71. Eukaryotic translation initiation factor 3 subunit G promotes human colorectal cancer.
Yang C; Zhang Y; Du W; Cheng H; Li C
Am J Transl Res; 2019; 11(2):612-623. PubMed ID: 30899366
[TBL] [Abstract][Full Text] [Related]
72. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives.
Pellino G; Gallo G; Pallante P; Capasso R; De Stefano A; Maretto I; Malapelle U; Qiu S; Nikolaou S; Barina A; Clerico G; Reginelli A; Giuliani A; Sciaudone G; Kontovounisios C; Brunese L; Trompetto M; Selvaggi F
Gastroenterol Res Pract; 2018; 2018():2397863. PubMed ID: 30008744
[TBL] [Abstract][Full Text] [Related]
73. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
74. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.
Françoso A; Simioni PU
Drug Des Devel Ther; 2017; 11():177-184. PubMed ID: 28138221
[TBL] [Abstract][Full Text] [Related]
75. Clinical Versus Research Sequencing.
Shevchenko Y; Bale S
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27638353
[TBL] [Abstract][Full Text] [Related]
76. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
77. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
De Stefano A; Carlomagno C
World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
[TBL] [Abstract][Full Text] [Related]
78. The economic considerations and implications of the stratification of future oncology therapeutics.
Gazouli M; Souliotis K
Mol Diagn Ther; 2014 Aug; 18(4):403-8. PubMed ID: 24825754
[TBL] [Abstract][Full Text] [Related]
79. Personalized treatment for advanced colorectal cancer: KRAS and beyond.
Patel GS; Karapetis CS
Cancer Manag Res; 2013; 5():387-400. PubMed ID: 24294007
[TBL] [Abstract][Full Text] [Related]
80. Validation of a next-generation sequencing assay for clinical molecular oncology.
Cottrell CE; Al-Kateb H; Bredemeyer AJ; Duncavage EJ; Spencer DH; Abel HJ; Lockwood CM; Hagemann IS; O'Guin SM; Burcea LC; Sawyer CS; Oschwald DM; Stratman JL; Sher DA; Johnson MR; Brown JT; Cliften PF; George B; McIntosh LD; Shrivastava S; Nguyen TT; Payton JE; Watson MA; Crosby SD; Head RD; Mitra RD; Nagarajan R; Kulkarni S; Seibert K; Virgin HW; Milbrandt J; Pfeifer JD
J Mol Diagn; 2014 Jan; 16(1):89-105. PubMed ID: 24211365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
